Biblio
Karyotype plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) who Benefit from Intensive Post-Induction Consolidation Therapy. Am J Hematol. 2016.
. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629-637.